assignment
Not Recruiting

Evaluation of DFF332 Monotherapy and Combination with Everolimus or Immuno-oncology Agents in Advanced Relapsed Clear Cell Renal Cell Carcinoma

Trial ID
2024-513379-41-00
Protocol
CDFF332A12101

Register record, history and transparency: CTIS.eu

Trial statistics

location_city
3
research sites
public
3
countries
medical_information
1
disease
person_search
3
investigators

Diseases & Conditions

Renal cancer recurrent

Objectives

The primary objective of this study is to evaluate the efficacy and safety of **DFF332** as a monotherapy and in combination with **Everolimus** or immuno-oncology therapies in patients with advanced, relapsed **Clear Cell Renal Cell Carcinoma**. This is clinically relevant as it aims to explore potential therapeutic options for a condition with limited treatment alternatives, potentially improving patient outcomes and expanding available treatment regimens.

Participants

The clinical trial involves a total of **122 participants** diagnosed with **advanced, relapsed Clear Cell Renal Cell Carcinoma**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants were selected to include a vulnerable population, although specific selection criteria were not disclosed by the sponsor. The general health status of the participants is not specified, nor are any lifestyle considerations such as diet or physical activity. The trial does not provide detailed information on key inclusion or exclusion criteria.

Plans and Procedures

The clinical trial is designed to evaluate the efficacy and safety of **DFF332** alone and in combination with Everolimus or immuno-oncology therapies in patients with **advanced, relapsed Clear Cell Renal Cell Carcinoma** and other selected tumors. This study is a Phase 1 trial, characterized by a randomized, double-blind, and controlled design. The trial commenced on January 26, 2022, and is projected to conclude by February 24, 2025. Participants will be involved in the study for its entire duration unless specific conditions necessitate early termination, such as adverse reactions or withdrawal of consent.

The sequence of study visits begins with an inclusion (screening) visit, where eligibility is assessed based on predefined criteria. Following successful screening, participants will undergo a series of follow-up visits at regular intervals to monitor treatment response and safety. These visits will include clinical assessments, laboratory tests, and imaging studies as required by the protocol. The end-of-study visit will occur at the conclusion of the treatment period, where final evaluations will be conducted to assess the overall outcomes and any long-term effects of the treatment.

Participants are expected to adhere to the study schedule and protocol requirements throughout their involvement. Conditions that may lead to early termination from the study include significant protocol deviations, development of exclusion criteria during the trial, or any medical condition that, in the investigator's judgment, may compromise the participant's safety or the integrity of the study data. The trial aims to provide valuable insights into the potential therapeutic benefits and risks associated with the investigational treatments for this patient population.

Treatment

The clinical trial documentation does not provide specific details regarding the experimental medication, including its **pharmaceutical form**, dosage, route, or frequency of administration. Additionally, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, that may be used in the study. Furthermore, the documentation lacks details on drug administration, dosing schedules, and participant compliance monitoring. As such, no further description of the treatments used in this clinical trial can be provided based on the available data.

Efficacy

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on January 26, 2022, with an estimated completion date of February 24, 2025. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize various parameters such as **biomarker levels** or symptom improvement scores to gauge initial efficacy signals. Data collection and analysis will be conducted according to the standard protocols for Phase 1 trials, ensuring rigorous and systematic evaluation of the investigational product's effects. The trial will adhere to established methodologies for measuring and analyzing efficacy parameters, although specific tools or instruments are not specified in the available data.

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Czechia CzechiaNot Recruiting26 Jan 202210
France FranceNot Recruiting26 Jan 202212
Spain SpainNot Recruiting26 Jan 20226

Sites & Investigators

Conditions Studied in This Trial